AtriCure’s EPi-Sense Afib Treatment Approved by FDA

 FDA approval results in the only label of its kind for more than 3 million patients in the United States, significantly expanding AtriCure’s addressable market

Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for long-standing persistent Afib patients.

Study also showed improved Electrophysiology Lab efficiency

https://finance.yahoo.com/news/atricure-epi-sense-system-approved-110000221.html